2017 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality

WALTHAM, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Oscar Sanchez as vice president of quality effective immediately.  He will report to Joseph Vittiglio, general counsel and senior vice president of legal affairs and qualit... More > 

AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Second quarter 2017 GAAP revenue increased 24% over same period last year  IntrarosaTM (prasterone) now commercially available  Completed Feraheme® (ferumoxytol) submission to FDA to broaden label beyond chronic kidney disease  Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Aug... More > 

AMAG Completes Feraheme® (ferumoxytol) FDA Submission for the Treatment of All Adult Patients With Iron Deficiency Anemia

Filing includes results of head-to-head Phase 3 clinical trial evaluating Feraheme compared to ferric carboxymaltose injection Potential approval and launch in the first half of 2018 WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has... More > 

AMAG Pharmaceuticals Launches Intrarosa™ (prasterone) in the U.S. – a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause

Intrarosa addresses an unmet need for women with moderate to severe dyspareunia, a common symptom of vulvar and vaginal atrophy, due to menopause Launch includes best-in-class copay savings program to help ensure swift and affordable access to Intrarosa for millions of women WALTHAM, Mass., July... More > 

AMAG Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Thursday, August 3, 2017 at 8:00 a.m. ET

WALTHAM, Mass., July 20, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its second quarter 2017 financial results will be released on Thursday, August 3, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 ... More > 

AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector

WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug application (sNDA) for the Makena® subcutaneous auto-injector, a drug-device combination product. The agenc... More > 

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio

WALTHAM, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Velo Bio, LLC has enrolled the first patient in a Phase 2b/3a study designed to evaluate the efficacy and safety of digoxin immune fab (DIF), a polyclonal antibody in development for the... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Jefferies 2017 Global Healthcare Conference Tuesday, June 6, 2017 at 9:30 a.m. ET Location: New York, N... More > 

AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs

WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Helen Milton, Ph.D., to the role of vice president of regulatory affairs. Dr. Milton will have responsibility for AMAG’s regulatory activities, including leading the strateg... More > 

AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy

Transactions extend maturities and reduce total debt by approximately 18% WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it has paid in full the remaining balance of $321 million of its term loan, which was due in 2021. This transact... More > 

AMAG Pharmaceuticals to Host Analyst Day on May 24th in New York

WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 24, 2017 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of AMAG’s management team and industry experts will ... More > 

AMAG Pharmaceuticals Announces Pricing of $300 Million of 3.25% Convertible Senior Notes Due 2022

WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced the pricing of $300 million aggregate principal amount of 3.25% Convertible Senior Notes due 2022 (the "notes") in an underwritten public offering (the "offering") registered under th... More > 

AMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due 2022

WALTHAM, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of Convertible Senior Notes due 2022 (the "notes") in an underwritten public ... More > 

AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update

First quarter 2017 GAAP revenue increased 28% Company announced positive Feraheme Phase 3 data Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for t... More > 

AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study

Achieved all primary and secondary safety and efficacy endpoints On track to file sNDA mid-year with a potential approval and launch in first half of 2018 Company to discuss clinical data on first quarter earnings call today at 8am ET WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- AMAG Phar... More > 

AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference

WALTHAM, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET. A live audio webcast will be accessi... More > 

AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance

WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Arpad Simon, M.D., to the role of vice president of pharmacovigilance. Dr. Simon has worked in the pharmaceutical industry for more than 20 years with extensive operationa... More > 

AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tuesday, May 2, 2017 at 8:00 a.m. ET

WALTHAM, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2017 financial results will be released on Tuesday, May 2, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m.... More > 

AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use

FDA Decision Anticipated on sNDA filing in the Fourth Quarter 2017 WALTHAM, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the Ma... More > 

AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa™ (Prasterone)

Anticipated U.S. launch in mid-2017 WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today the closing of the licensing agreement with Endoceutics, Inc. for the U.S. commercial rights to IntrarosaTM (prasterone). Intrarosa is the only FDA-appro... More > 

AMAG Pharmaceuticals to Present at the Needham Healthcare Conference

WALTHAM, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET. A live audio webcast will be accessible through the Investors sect... More > 

AMAG Announces Management Changes and New Commercial Appointments

WALTHAM, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced changes to the company’s executive and commercial leadership teams, including that Frank Thomas, president and chief operating officer, intends to transition out of the organization on April... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Cowen and Company Annual Health Care Conference  Monday, March 6, 2017 at 2:40 p.m. ET   Location: Bo... More > 

AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting

Both Phase 3 RECONNECT studies met co-primary endpoints and demonstrated significant improvement in key symptoms of hypoactive sexual desire disorder ... More > 

AMAG Reports Fourth Quarter and Full Year 2016 Financial Results

2016 GAAP revenue increased 27% over 2015 Achieved record quarterly and annual net sales for Makena® and Feraheme® Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated f... More > 

AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)

Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause Conference call sch... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conference

WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017 at 2:00 p.m. EST. A live audio webcast ... More > 

AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Tuesday, February 14, 2017 at 8:00 a.m. ET

WALTHAM, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will report financial results for the fourth quarter and year ended December 31, 2016 on Tuesday, February 14, 2017 before the U.S. financial markets open. Management will host a conf... More > 

AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide)

Anticipated new drug application (NDA) filing in early 2018 WALTHAM, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today the closing of the licensing agreement with Palatin Technologies, Inc. for exclusive North American commercial rights to RekyndaTM... More > 

AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration

Supplemental new drug application on track for second quarter 2017 filing WALTHAM, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced results from its definitive pharmacokinetic (PK) study designed to demonstrate comparable bioavailability of the sub... More > 

AMAG Pharmaceuticals Provides Financial and Business Update

2016 total revenue increased 45 percent Provides update on Makena® next-generation program Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provi... More > 

AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

Two Phase 3 trials completed for Rekynda; co-primary endpoints met Will address underserved medical condition with significant untapped market potential Broadens AMAG’s presence in women’s health and leverages AMAG’s commercial capabilities and customer relationships WALTHAM, Mass. and CRANBURY... More > 

AMAG Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time... More >